Drug news
FDA rejects Prochieve(Watson Pharma) for risk reduction in PreTerm Birth
Watson Pharma has received a complete response letter from the FDA for its New Drug Application for Prochieve ( progesterone vaginal gel 8%) for use in the reduction of risk of Preterm Birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins